公开(公告)号：EP4219689A3

公开(公告)日：2023-12-20

申请号：EP23152887.8

申请日：2016-12-30

申请人： Novartis AG ,  The Trustees of The University of Pennsylvania

发明人： MOTZ, Gregory ,  MAVRAKIS, Konstantinos John ,  LIU, Jinbiao ,  LIU, Lei ,  ZHENG, Qiangang ,  XUN, Guoliang ,  XIAO, Qitao

IPC分类号： C12N5/0783 ,  C12N15/113 ,  C07D295/00 ,  C07D401/14 ,  A61K35/17 ,  C07D207/34 ,  C07K16/24 ,  C07K16/28 ,  C07K16/30 ,  A61P35/00

摘要： The present invention relates generally to the use of LSD1 inhibitors in connection with use and manufacture of immune effector cells (e.g., T cells, NK cells), e.g., engineered to express a chimeric antigen receptor (CAR), to treat a subject having a disease, e.g., a disease associated with expression of a tumor antigen.

公开(公告)号：EP3523290A1

公开(公告)日：2019-08-14

申请号：EP17854999.4

申请日：2017-09-29

申请人： Novartis AG ,  The Trustees of The University of Pennsylvania

发明人： MOTZ, Gregory ,  MAVRAKIAS, Konstantinos John ,  LIU, Jinbiao ,  LIU, Lei ,  ZHENG, Qiangang ,  XUN, Guoliang ,  XIAO, Qitao

IPC分类号： C07D401/04 ,  C07D209/14 ,  A61K31/33 ,  A61P35/00

公开(公告)号：EP3350320A1

公开(公告)日：2018-07-25

申请号：EP16779217.5

申请日：2016-09-16

申请人： Novartis AG ,  The Trustees of The University of Pennsylvania ,  Bushman, Frederic Dixon ,  Fraietta, Joseph A. ,  June, Carl, H. ,  Melenhorst, Jan J. ,  Nobles, Christopher Loren ,  Young, Regina M.

发明人： BUSHMAN, Frederic, Dixon ,  FRAIETTA, Joseph, A. ,  JUNE, Carl, H. ,  MELENHORST, Jan, J. ,  NOBLES, Christopher, Loren ,  YOUNG, Regina, M. ,  MOTZ, Gregory

IPC分类号： C12N9/02 ,  C07K14/705

CPC分类号： C07K14/4748 ,  A61K35/17 ,  A61K39/0011 ,  A61K39/39558 ,  A61K2039/5154 ,  A61K2039/5156 ,  A61K2039/5158 ,  A61P35/00 ,  C07K14/70503 ,  C12N9/0069 ,  C12Y113/11

摘要： The invention provides compositions and methods improved CAR T cell therapies. Specifically, the invention provides cells with reduced Tet, e.g., Tet2 function or expression, and methods of use therefore. The invention further provides Tet2 inhibitors and methods of use therefore in connection with CAR T cells.

公开(公告)号：EP4219721A3

公开(公告)日：2023-09-06

申请号：EP23151319.3

申请日：2017-04-14

申请人： Novartis AG ,  The Trustees of The University of Pennsylvania

发明人： GOLOSOV, Andrei ,  GUIMARAES, Carla ,  MOTZ, Gregory ,  MILONE, Michael ,  ELLEBRECHT, Christoph T. ,  PAYNE, Aimee S.

IPC分类号： C12N15/62 ,  C07K14/725

摘要： Provided herein are fusion proteins including two protein domains separated by a heterologous protease cleavage site, wherein a first of the protein domains is a conditional expression domain. Thus, the fusion proteins comprise three essential elements: a conditional expression domain, a domain containing the protein of interest, and a protease cleavage domain separating the two.
Also provided herein are methods for treating autoantibody and alloantibody-mediated diseases or conditions in a subject by targeting B cells with anti-B cell modified T cells. In one embodiment, a chimeric antigen receptor (CAR) modified T cell is selectively ablated in a subject after adoptive transfer.
Pharmaceutical compositions comprising the temporally regulated CAR modified T cell are also described herein.

公开(公告)号：EP3443096A2

公开(公告)日：2019-02-20

申请号：EP17737079.8

申请日：2017-04-14

申请人： Novartis AG ,  The Trustees of The University of Pennsylvania

发明人： GOLOSOV, Andrei ,  GUIMARAES, Carla ,  MOTZ, Gregory ,  MILONE, Michael ,  ELLEBRECHT, Christoph, T. ,  PAYNE, Aimee, S.

IPC分类号： C12N15/62 ,  C07K14/725

公开(公告)号：EP4219721A2

公开(公告)日：2023-08-02

申请号：EP23151319.3

申请日：2017-04-14

申请人： Novartis AG ,  The Trustees of The University of Pennsylvania

发明人： GOLOSOV, Andrei ,  GUIMARAES, Carla ,  MOTZ, Gregory ,  MILONE, Michael ,  ELLEBRECHT, Christoph T. ,  PAYNE, Aimee S.

IPC分类号： C12N15/62 ,  C07K14/725

摘要： Provided herein are fusion proteins including two protein domains separated by a heterologous protease cleavage site, wherein a first of the protein domains is a conditional expression domain. Thus, the fusion proteins comprise three essential elements: a conditional expression domain, a domain containing the protein of interest, and a protease cleavage domain separating the two.
Also provided herein are methods for treating autoantibody and alloantibody-mediated diseases or conditions in a subject by targeting B cells with anti-B cell modified T cells. In one embodiment, a chimeric antigen receptor (CAR) modified T cell is selectively ablated in a subject after adoptive transfer.
Pharmaceutical compositions comprising the temporally regulated CAR modified T cell are also described herein.

公开(公告)号：EP4219689A2

公开(公告)日：2023-08-02

申请号：EP23152887.8

申请日：2016-12-30

申请人： Novartis AG ,  The Trustees of The University of Pennsylvania

发明人： MOTZ, Gregory ,  MAVRAKIAS, Konstantinos John ,  LIU, Jinbiao ,  LIU, Lei ,  ZHENG, Qiangang ,  XUN, Guoliang ,  XIAO, Qitao

IPC分类号： C12N5/0783 ,  C12N15/113 ,  C07D295/00 ,  C07D401/14 ,  A61K35/17 ,  C07D207/34 ,  C07K16/24 ,  C07K16/28 ,  C07K16/30 ,  A61P35/00

摘要： The present invention relates generally to the use of LSD1 inhibitors in connection with use and manufacture of immune effector cells (e.g., T cells, NK cells), e.g., engineered to express a chimeric antigen receptor (CAR), to treat a subject having a disease, e.g., a disease associated with expression of a tumor antigen.

公开(公告)号：EP3697436A1

公开(公告)日：2020-08-26

申请号：EP18808556.7

申请日：2018-10-18

申请人： Novartis AG

发明人： BRADNER, James, E. ,  GOLOSOV, Andrei ,  GOOLD, Carleton, Proctor ,  GUIMARAES, Carle, Patricia Pinto ,  HILD, Marc Horst Peter ,  MOTZ, Gregory ,  ROSS, Nathan Thomas ,  SOLOMON, Jonathan, M. ,  BECKWITH, Rohan, Eric John ,  CARBONNEAU, Seth

IPC分类号： A61K39/00 ,  A61K31/454 ,  C07K14/47 ,  A61P35/00 ,  C07K16/00 ,  C07K16/28